Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acadia Pharmaceutica (NQ: ACAD )

24.61 +0.71 (+2.97%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Acadia Pharmaceutica

< Previous 1 2 3 4 5 6 Next >
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
 
Via Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
 
Via Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
 
Via Benzinga
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else? 
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
 
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
 
Via Benzinga
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
 
Via Benzinga
1 Top Biotech Stock to Buy in March
This biotech could land a major regulatory approval this month. 
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older. 
Via Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on... 
Via Benzinga
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of... 
Via Benzinga
Looking Into ACADIA Pharmaceuticals's Return On Capital Employed
 
Via Benzinga
Analysts See Steady Growth For Acadia Pharma's Nuplazid
 
Via Benzinga
3 Nasdaq Stocks on Watch This Week
These three Nasdaq stocks are poised to make big moves in the coming week. 
Via The Motley Fool
What 10 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
 
Via Benzinga
Mizuho Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022
Upgrades 
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Earnings Preview For ACADIA Pharmaceuticals
 
Via Benzinga
Analyst Expectations for ACADIA Pharmaceuticals's Future
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary
 
Via Benzinga
U.S. FDA Accepts Acadia's Filing For Rett Syndrome Candidate Under Priority Review
The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory... 
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar. 
Via Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data, during Q2, ACADIA Pharmaceuticals (NASDAQ:ACAD) posted sales of $134.56 million. Earnings were up 69.92%, but ACADIA Pharmaceuticals still reported an overall loss of... 
Via Benzinga
Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data
 
Via Benzinga
ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.